NCT06227728Recruiting
Analysis of PD-L1, TMB, MSI and ctDNA Dynamics to Predict and Monitor Response to Immunotherapy in Metastatic Cancer.
Analysis of PD-L1, TMB, CTDNA in Immunotherapy Response Monitoring and Prediction in Advancer Lung Cancer Treatment.
Source: ClinicalTrials.gov · Last updated 16 Jan 2026
Brief summary (registry, in English)
This is an observational clinical trial, aiming to investigate whether the ctDNA dynamics could predict early response to ICIs in patients with advanced-stage cancer. Moreover, conventional tumor markers PD-L1, TMB and MSI are to be investigated for their combined prognostic values in ICI treatment.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 50 (estimated)
- First submitted
- 18 Jan 2024
- Start date
- 22 Mar 2024
- Primary completion date
- 1 Dec 2026
- Lead sponsor
- Gene Solutions
- Diseases
- Lung cancer, Colorectal cancer, Liver and biliary tract cancer, Gastric and esophageal cancer
- NCT number
- NCT06227728
What you commit to
- Study type: Observational
- Planned participants: 50
- From 22 Mar 2024 to the primary completion date, 1 Dec 2026
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients already started chemotherapy before enrollment.
Other illness
- Medical or psychiatric conditions or occupational responsibilities that may preclude compliance with the protocol.
Other
- Patients already started ICI before enrollment.
- Consolidation ICI (eg. Durvalumab).
- Patients did not agree to participate in the studies.
Who the study is looking for
- 18 years and older, both genders.
- Patients are diagnosed with stage IV cancer (lung, colorectal, breast, liver, gastric…) and indicated for ICI (first or second line). Concurrent chemotherapy with ICI is allowed.
- FFPE/FNA sample is available.
- Compliant with treatment protocol.
- Patients consented to participate in the study.
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Medicine and Pharmacy at HCMC Coordinator of this site? Confirm its status | Ho Chi Minh City | Vietnam | Recruiting |
| Medical Genetics Institute Coordinator of this site? Confirm its status | Ho Chi Minh City | Vietnam | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.